Cite
HARVARD Citation
Jones, R. et al. (2021). A pharmacokinetic–pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti‐tumour activity. British journal of pharmacology. pp. 600-613. [Online].